LMNA and familial dilated cardiomyopathy: Prediction will be especially important for dilated cardiomyopathy (DCM), where potentially pathogenic LMNA mutations are seen in 5.3 to 6.5% of patients (Lakdawala et al., 2012; Pugh et al., 2014) and exhibit a high incidence of phenotypic progression with adverse clinical outcomes (Kumar et al., 2016).